Micra AV provides AV synchrony
Allowing more of your patients to benefit from leadless pacing.2
Micra
Transcatheter Pacing System
for Bradyarrhythmia Management
The Micra™ transcatheter pacing system (TPS) is the world’s smallest pacemaker,1 delivered percutaneously via a minimally invasive approach, directly into the right ventricle and does not require the use of leads.
Download Micra BrochureOverview
Meet Micra AV Now with AV Synchrony2, 11
The Future is Here
Allowing more of your patients to benefit from leadless pacing.
UNMATCHED LEADLESS PACING EXPERIENCE
Redefined Patient Experience.
- No chest scar or bump
- Fewer post-implant activity restrictions
Eliminated Pocket-related Complications3
- Infection
- Hematoma
- Erosion
Eliminated Lead-related Complications3
- Fractures
- Insulation breaches
- Venous thrombosis and obstruction
- Tricuspid regurgitation
93% Smaller than transvenous pacemakers4
Now Offering Two Leadless Pacing Options
| Parameter |
Micra AV5 |
Micra VR6 |
|---|---|---|
| Pacing Mode |
VVI, VVIR, VOO, OVO, VDD, VDI, ODO, OFF |
VVI, VVIR, VOO, OVO, OFF |
| Mass |
1.75 g |
1.75 g |
| Volume |
0.8 cc |
0.8 cc |
| Electrode Spacing |
18 mm |
18 mm |
| Battery Longevity |
8-13 years†5,7 |
12 years‡8 |
| Accelerometer-based Mechanical Atrial Sensing |
Yes |
N/A |
| Accelerometer-based Rate Response |
Yes |
Yes |
| MRI SureScan™ |
1.5T & 3T |
1.5T & 3T |
AV Synchrony REIMAGINED
- Accelerometer detects mechanical atrial activity and uses this information to deliver AV synchronous ventricular pacing.2
- New, integrated circuitry capable of sustaining new AV synchrony functionality.2
- 11 new algorithms,2 including:
- AV Conduction Mode Switch
- Rate Smoothing
- Activity Mode Switch
- Delivers an estimated average battery longevity of 8-13 years, dependent on patient’s degree of AV block.5,7
SAME, STREAMLINED PROCEDURE
Micra Integrated Delivery Catheter
105 cm long catheter system with a handle that controls deflection and deployment of the Micra pacing capsule.6
- Device deployment button
- Curve deflection button
- Tether lock button
- Tether pin
- Flush port
Smooth Vessel Navigation with the Micra Introducer
- Lubricious hydrophilic coating
- 23 Fr inner diameter (27 Fr outer diameter)
- Silicone oil-coated dilator tip
- Extended distal taper
- 56 cm (22 in) working length
- Side port with 3-way stopcock
CLINICAL EVIDENCE
Micra AV Algorithm Performance11
The MARVEL 2 trial is a multicenter, pivotal IDE study in which the MARVEL 2 algorithm was downloaded into existing Micra VR devices in order to provide AV synchronous pacing.
- 94.3% median AV synchrony at rest in complete AV block patients with normal sinus rhythm (n = 40)
- Mean AV synchrony increased from 26.8% during VVI pacing to 89.2%
- 95% of patients (38 of 40) with complete AV block and normal sinus rhythm had ≥ 70% AV synchrony
- 8.8% improvement in stroke volume as measured by LVOT VTI (n = 39)
Micra VR procedural PERFORMANCE10, 12
Real-world experience reinforces safety and long-term performance of Micra VR.
- > 99% implant success rate in Micra VR* clinical studies
- Low major complication rate through 12 months (2.7%)
- Low dislodgement rate (0.06%)
- Low procedure-related infection rate (0.17%)
- 63% fewer major complications than traditional pacemakers
Micra videos
Learn about the Micra VR design journey
More information (see more)
Less information (see less)
Micra AV transcatheter pacing system (TPS), the world smallest pacemaker
More information (see more)
Less information (see less)
Model Specifications
*
The single chamber Micra™ Transcatheter Pacing System is being described herein as Micra™ VR in order to distinguish it from Micra™ AV product. When information in this document related to both Micra AV and VR, “Micra™ Transcatheter Pacing Systems” is used to represent the portfolio of devices. Micra AV real world data not yet available.
†
Use conditions include:
8 years = 100% VDD pacing, 60 bpm, pacing threshold 1.5 V, impedance 500 Ω, pulse width 0.24 ms.
13 years = 15% VDD pacing, 70 bpm, pacing threshold 1.5 V, impedance 600 Ω, pulse width 0.24 ms.
‡
Use conditions included: median pacing 53.5%, median pacing threshold 0.50 V, median impedance 543 Ω; 89% of patients with > 10-year projected longevity; 99% of patients with > 5-year longevity.12
References
1
Nippoldt D, Whiting J. Micra Transcatheter Pacing System Device Volume Characterization Comparison. November 2014. Medtronic data on file.
2
Medtronic Micra™ AV MC1AVR1 Reference Manual. March 2020.
3
Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. May 2012;9(5):728-735.
4
Williams E, Whiting J. Micra Transcatheter Pacing System Size Comparison. November 2014. Medtronic data on file.
5
Medtronic Micra™ AV MC1AVR1 Device Manual. March 2020.
6
Medtronic Micra™ MC1VR01 Clinician Manual. April 2015.
7
Pender J, Whiting J. Micra AV Battery Longevity. January 2020. Medtronic data on file.
8
Duray GZ, Ritter P, El-Chami M et al. Long-term performance of a transcatheter pacing system: 12-Month Results from the Micra Transcatheter Pacing Study. Heart Rhythm. May 2017;14(5):702-709.
9
Reynolds D, Duray GZ, Omar R, et al. A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med. February 11, 2016;374(6):533-541.
10
El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Heart Rhythm. December 2018;15(12):1800-1807.
11
Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular synchronous pacing using a leadless ventricular pacemaker: Results from the MARVEL 2 Study. JACC Clin Electrophysiol. 2020;6(1):94-106.
12
Ritter P, et al. Long-Term Performance of a Transcatheter Pacing System: 12-month results from the Micra Global Clinical Trial. LBCT presentation at ESC 2016; Rome, Italy.